A detailed history of Virtu Financial LLC transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtu Financial LLC holds 13,748 shares of ATNM stock, worth $16,635. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,748
Previous 20,970 34.44%
Holding current value
$16,635
Previous $155,000 83.23%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 20, 2024

SELL
$1.72 - $8.0 $12,421 - $57,776
-7,222 Reduced 34.44%
13,748 $26,000
Q2 2024

Aug 09, 2024

SELL
$6.56 - $9.89 $400,547 - $603,873
-61,059 Reduced 74.44%
20,970 $155,000
Q1 2024

May 20, 2024

BUY
$5.0 - $9.2 $312,295 - $574,622
62,459 Added 319.16%
82,029 $642,000
Q4 2023

Feb 26, 2024

BUY
$4.02 - $6.08 $78,671 - $118,985
19,570 New
19,570 $99,000
Q1 2023

May 01, 2023

SELL
$8.51 - $14.26 $44,286 - $74,209
-5,204 Reduced 19.38%
21,650 $205,000
Q4 2022

Feb 15, 2023

BUY
$7.05 - $14.41 $100,561 - $205,544
14,264 Added 113.3%
26,854 $286,000
Q3 2022

Nov 07, 2022

SELL
$4.81 - $8.48 $111,587 - $196,727
-23,199 Reduced 64.82%
12,590 $93,000
Q2 2022

Aug 09, 2022

BUY
$4.71 - $7.11 $102,202 - $154,279
21,699 Added 154.0%
35,789 $172,000
Q1 2022

May 17, 2022

BUY
$4.57 - $6.4 $319 - $448
70 Added 0.5%
14,090 $72,000
Q4 2021

Feb 17, 2022

BUY
$6.01 - $8.8 $84,260 - $123,376
14,020 New
14,020 $84,000
Q1 2021

May 19, 2021

SELL
$7.62 - $9.79 $209,732 - $269,459
-27,524 Closed
0 $0
Q4 2020

Feb 24, 2021

BUY
$7.8 - $12.64 $214,687 - $347,903
27,524 New
27,524 $215,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $30.5M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.